Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6796490 | 0.83 | PDPK1 (0.45) | PDPK1ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL11475921 | 0.79 | PDPK1 (0.39) | PDPK1PDE5ANOS3NOS2LMNA | |
| SCHEMBL6233405 | 0.77 | PDE5A (0.46) | PDPK1PDE5ALMNAMAPTMAP4K4 | |
| SCHEMBL7519562 | 0.77 | — | — | |
| SCHEMBL12051534 | 0.76 | PDPK1 (0.41) | PDPK1ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL38661744 | 0.76 | PDPK1 (0.37) | PDPK1PDE5ANOS3NOS2ALDH1A1 | |
| SCHEMBL15334043 | 0.76 | PDPK1 (0.37) | PDPK1PDE5ALMNAMAPTMAP4K4 | |
| SCHEMBL2900733 | 0.75 | PDPK1 (0.43) | PDPK1PDE5ANOS3NOS2ALDH1A1 | |
| SCHEMBL23717803 | 0.73 | PDPK1 (0.38) | PDPK1ALDH1A1MAPTSMN1; SMN2HSD17B10 | |
| SCHEMBL16399428 | 0.73 | PDPK1 (0.38) | PDPK1ALDH1A1MAPTSMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270198-A1 | PYRIDONE COMPOUNDS AS TRPA1 INHIBITORS | D. E. SHAW RESEARCH, LLC | 2025-08-28 | — | — | US | disclosed |
| EP-4519250-A1 | PYRIDONE COMPOUNDS AS TRPA1 INHIBITORS | D.E. Shaw Research, LLC (US) | 2025-03-12 | — | — | EP | disclosed |
| CN-119451948-A | Pyridone compounds as TRPA1 inhibitors | D·E·萧尔研究有限责任公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2023215775-A1 | PYRIDONE COMPOUNDS AS TRPA1 INHIBITORS | D. E. SHAW RESEARCH, LLC (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215775-A1 | PYRIDONE COMPOUNDS AS TRPA1 INHIBITORS | D. E. SHAW RESEARCH, LLC (US) | 2023-11-09 | — | — | WO | disclosed |
| US-9738644-B2 | Chemical compounds, compositions and methods for kinase modulation | INFINITY PHARMACEUTICALS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160016957-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. | 2016-01-21 | — | — | US | disclosed |
| US-9181221-B2 | Chemical compounds, compositions and methods for kinase modulation | INFINITY PHARMACEUTICALS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140088099-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
| US-20100210667-A1 | IMIDAZO [1, 2-C] PYRIMIDIN-2-YLMETHYLPIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | ALVARO GIUSEPPE | 2010-08-19 | — | — | US | disclosed |
| US-20100210667-A1 | IMIDAZO [1, 2-C] PYRIMIDIN-2-YLMETHYLPIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | ALVARO GIUSEPPE | 2010-08-19 | — | — | US | disclosed |
| US-20100210667-A1 | IMIDAZO [1, 2-C] PYRIMIDIN-2-YLMETHYLPIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | ALVARO GIUSEPPE | 2010-08-19 | — | — | US | disclosed |
| EP-2176265-A1 | IMIDAZO [1, 2-C]PYRIMIDIN-2-YLMETHYLPIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | Glaxo Group Limited (GB) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009003997-A1 | IMIDAZO [1, 2-C] PYRIMIDIN-2-YLMETHYLPIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009003997-A1 | IMIDAZO [1, 2-C] PYRIMIDIN-2-YLMETHYLPIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | LIMK1 470/4885L3MBTL1 2853/4885PDPK1 22/4885 |
| US-20140088099-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | LIMK1 470/4885L3MBTL1 2853/4885PDPK1 22/4885 |
| US-20100210667-A1 | IMIDAZO [1, 2-C] PYRIMIDIN-2-YLMETHYLPIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | LIMK1 4636/4885L3MBTL1 4464/4885PDPK1 1083/4885 |
| US-20160016957-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | LIMK1 470/4885L3MBTL1 2853/4885PDPK1 22/4885 |
| US-20250270198-A1 | PYRIDONE COMPOUNDS AS TRPA1 INHIBITORS | TRPA1, TRPV1, TRPV6 | LIMK1 1393/4885L3MBTL1 3737/4885PDPK1 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.